BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24878890)

  • 1. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.
    Kosaka A; Ohkuri T; Okada H
    Cancer Immunol Immunother; 2014 Aug; 63(8):847-57. PubMed ID: 24878890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
    Fujita M; Kohanbash G; Fellows-Mayle W; Hamilton RL; Komohara Y; Decker SA; Ohlfest JR; Okada H
    Cancer Res; 2011 Apr; 71(7):2664-74. PubMed ID: 21324923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.
    Shoji T; Saito R; Chonan M; Shibahara I; Sato A; Kanamori M; Sonoda Y; Kondo T; Ishii N; Tominaga T
    Neuro Oncol; 2016 Aug; 18(8):1120-8. PubMed ID: 26917236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment.
    van Hooren L; Georganaki M; Huang H; Mangsbo SM; Dimberg A
    Oncotarget; 2016 Jul; 7(31):50277-50289. PubMed ID: 27385210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.
    Medina-Echeverz J; Ma C; Duffy AG; Eggert T; Hawk N; Kleiner DE; Korangy F; Greten TF
    Cancer Immunol Res; 2015 May; 3(5):557-66. PubMed ID: 25637366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.
    Liu C; Lewis CM; Lou Y; Xu C; Peng W; Yang Y; Gelbard AH; Lizée G; Zhou D; Overwijk WW; Hwu P
    J Immunother; 2012 Apr; 35(3):276-82. PubMed ID: 22421945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
    Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Murine Fibroblastic Reticular Cells From Lymph Node Interact With CD4+ T Cells Through CD40-CD40L.
    Nakayama Y; Brinkman CC; Bromberg JS
    Transplantation; 2015 Aug; 99(8):1561-7. PubMed ID: 25856408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.
    Ninomiya A; Ogasawara K; Kajino K; Takada A; Kida H
    Vaccine; 2002 Aug; 20(25-26):3123-9. PubMed ID: 12163263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of antitumor activity by combination of tumor lysate-pulsed dendritic cells and celecoxib in a rat glioma model.
    Zhang H; Tian M; Xiu C; Wang Y; Tang G
    Oncol Res; 2013; 20(10):447-55. PubMed ID: 24308155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
    Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
    PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
    Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
    J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agonistic CD40 antibodies and cancer therapy.
    Vonderheide RH; Glennie MJ
    Clin Cancer Res; 2013 Mar; 19(5):1035-43. PubMed ID: 23460534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
    Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
    Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.
    Zhang M; Ju W; Yao Z; Yu P; Wei BR; Simpson RM; Waitz R; Fassò M; Allison JP; Waldmann TA
    J Immunol; 2012 Jun; 188(12):6156-64. PubMed ID: 22593619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.
    Buhtoiarov IN; Lum H; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
    J Immunol; 2005 May; 174(10):6013-22. PubMed ID: 15879094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.
    Zhang B; Ma X; Li Z; Gao X; Wang F; Liu L; Shen G; Sang Y; Li M; Li Y; Zhao J; Wei Y
    J Cancer Res Clin Oncol; 2013 May; 139(5):797-807. PubMed ID: 23385883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma.
    van Hooren L; Vaccaro A; Ramachandran M; Vazaios K; Libard S; van de Walle T; Georganaki M; Huang H; Pietilä I; Lau J; Ulvmar MH; Karlsson MCI; Zetterling M; Mangsbo SM; Jakola AS; Olsson Bontell T; Smits A; Essand M; Dimberg A
    Nat Commun; 2021 Jul; 12(1):4127. PubMed ID: 34226552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
    Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
    Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
    van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
    J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.